In general, semaglutide (Wegovy ) and tirzepatide (Zepbound ) are FDA-approved for weight loss in people with: A BMI of 30 or higher , or A BMI of 27 or higher with at least one weight-related condition, like type 2 diabetes or high blood pressure Each medication also has additional FDA-approved uses beyond weight loss: Wegovy is also approved to reduce the risk of major cardiovascular events like heart attack and stroke in adults with cardiovascular disease
Step 4: Pinch and inject With your non-dominant hand, gently pinch about 1-2 inches of skin and subcutaneous tissue at the injection site
The medication carries a black box warning about thyroid C-cell tumors, but no human cases have been definitively linked to GLP-1 agonist use
We make this in a patent-pending base that helps absorb the larger semaglutide molecule As of April 22, 2025, the compounded injectable semaglutide will no longer be available due to the FDAs declaration of drug shortages being removed
Accessibility and Convenience: Evaluate how easy it is to schedule consultations, access prescriptions, and communicate with medical professionals
